Does @entity3175 really reduce the cardiotoxic effects of intravenous XXXX ?

@entity3175 @entity137 @entity943 @entity1341 @entity520 @entity35 @entity4710 @entity22292
The effect of @entity3175 on the cardiovascular @entity137 of @entity1341 was investigated in a @entity35 model. Under @entity22292 (400 mg/kg intraperitoneal) anesthesia, unilateral femoral venous and bilateral femoral arterial cannulae were placed for administration of drugs, for blood sampling, and for continuous qualitative monitoring of arterial blood pressure. Lead II ECG was continuously recorded and a tracheostomy performed to increase FIO2 by use of a "T-piece." Four groups of 24 to 36 @entity35 each were studied. All @entity35 received IV @entity1341 2 mg/kg, within 10 seconds. Group I, the control group, received only @entity1341 . Groups II and III received IV @entity3175 0.2 mg/kg, or @entity3175 vehicle in an equivalent volume, respectively. Five minutes after this pretreatment, groups II and III received IV @entity1341 2 mg/kg. Group IV was given @entity3175 , 0.2 mg/kg, 30 seconds after injection of 2 mg/kg @entity1341 . A marked respiratory and @entity520 occurred in all @entity35 but was significantly worse in groups II and III. No @entity35 in the study became hypoxemic. Serious @entity943 (ventricular or @entity4710 ) were noted in all groups, but the incidence was significantly higher in the group of @entity35 given @entity3175 pretreatment than in the other three groups. It is concluded that IV @entity3175 0.2 mg/kg given 5 minutes before administration of IV @entity1341 2 mg/kg increases the incidence of serious @entity943 . Second, this increase is not solely due to increased @entity520 , because the @entity35 receiving the vehicle (group III) developed equivalent @entity520 but did not develop increased @entity943 .
